TrialDrug safety2021

The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years.

Avy Violari et al.PubMed ↗Publisher ↗

No numbers read from the abstract.